Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
6 p, 1.5 MB Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future / Rao, M. (ImmunoSurgery Unit. Champalimaud Centre for the Unknown) ; Ippolito, G. (National Institute for Infectious Diseases. Lazzaro Spallanzani) ; Mfinanga, S. (National Institute of Medical Research Muhimbili) ; Ntoumi, F. (Institute for Tropical Medicine. University of Tübingen) ; Yeboah-Manu, D. (Noguchi Memorial Institute for Medical Research. Department of Bacteriology) ; Vilaplana, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zumla, Alimuddin (Division of Infection and Immunity. University College London and NIHR Biomedical Research Centre. UCL Hospitals NHS Foundation Trust) ; Maeurer, M. (Department of Oncology and Haematology. Krankenhaus Nordwest) ; Universitat Autònoma de Barcelona
Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. [...]
2019 - 10.1016/j.ijid.2019.01.039
International journal of infectious diseases, Vol. 80 (march 2019) , p. S62-S67  
2.
4 p, 362.8 KB Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground / Rao, M. (Champalimaud Centre for the Unknown) ; Ippolito, G. (National Institute for Infectious Diseases. Lazzaro Spallanzani) ; Mfinanga, S. (National Institute of Medical Research Muhimbili) ; Ntoumi, F. (University of Tübingen) ; Yeboah-Manu, D. (Noguchi Memorial Institute for Medical Research) ; Vilaplana, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zumla, Alimuddin (University College London) ; Maeurer, M. (Krankenhaus Nordwest) ; Universitat Autònoma de Barcelona
Latent tuberculosis infection (LTBI) is established in over 90% of persons infected with Mycobacterium tuberculosis (Mtb), from whom new active TB cases will arise. Understanding the spatio-temporal dynamics of host immune responses in LTBI granulomas is essential to designing effective post-exposure therapies that inhibit progression to TB. [...]
2019 - 10.1016/j.ijid.2019.02.035
International journal of infectious diseases, Vol. 80 (march 2019) , p. S58-S61  
3.
9 p, 608.4 KB Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis : A Systematic Review / Kroesen, Vera Marie (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gröschel, Matthias I. (Department of Infectious Diseases, University Medical Center Groningen, University of Groningen) ; Martinson, Neil (Perinatal HIV Research Unit, University of Witwatersrand) ; Zumla, Alimuddin (Department of Microbiology, University College London Hospitals NHS Foundation Trust) ; Maeurer, Markus (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ; van der Werf, Tjip S. (Department of Infectious Diseases, University Medical Center Groningen, University of Groningen) ; Vilaplana, Cristina (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional tuberculosis treatment, complicated by emerging drug resistances. Host-directed therapies, including non-steroidal anti-inflammatory drugs (NSAIDs), in contrast, target host factors to mitigate disease severity. [...]
2017 - 10.3389/fimmu.2017.00772
Frontiers in immunology, Vol. 8 (june 2017)  

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.